Table 3 Quality of evidence.

From: The combination of astragalus injection and ambroxol hydrochloride in the adjuvant treatment of COPD: a systematic review and meta-analysis

Quality assessment

No of patients

Effect

Quality

No of studies

Design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Test

Control

Relative (95% CI)

Absolute

CER

RCT

SeriousA

NS

NS

SeriousE

N

509/536

(95%)

416/534

(77.9%)

OR 5.44 (3.51 to 8.43)

171 more per 1000 (from 146 to 188 more)

⊕⊕OO

14 studies

Low

FEV1/FVC

RCT

SeriousA

NS

NS

SeriousB, E

SeriousC

150

150

–

MD 2.51 higher (-0.05 lower to 5.06 higher)

⊕OOO

4 studies

Very low

FEV1%

RCT

SeriousA

NS

NS

SeriousD, E

N

398

396

–

MD 16.18 higher (12.6 to 19.76 higher)

⊕OOO

10 studies

Very low

PaO2

RCT

SeriousA

NS

NS

SeriousE

N

284

282

–

MD 1.12 higher (0.87 to 1.36 higher)

⊕⊕OO

7 studies

Low

PaCO2

RCT

SeriousA

NS

NS

SeriousE

N

284

282

–

MD 1.43 lower (1.65 to 1.21 lower)

⊕⊕OO

7 studies

Low

FEV1

RCT

SeriousA

NS

NS

SeriousB

N

176

174

–

MD 0.3 higher (0.18 to 0.42 higher)

⊕⊕OO

5 studies

Low

FVC

RCT

SeriousA

NS

NS

SeriousE

N

212

210

–

MD 0.33 higher (0.21 to 0.45 higher)

⊕⊕OO

5 studies

Low

Hemoglobin

RCT

SeriousA

NS

NS

SeriousB, E

N

133

131

 

MD 16.17 lower (20.84 to 11.51 lower)

⊕OOO

3 studies

Very low

  1. NS Not serious, N none.
  2. AThe methodology of most studies has an unclear bias.
  3. BThe sample size was less than 400.
  4. CThe sensitivity analysis revealed a highly sensitive profile.
  5. DHeterogeneity test I2 > 75% (82%).
  6. EThe medication and dosage of routine therapy are unclear.